comprehensive -WSS

comprehensive

author：hotspot 2025-09-28 00:47:25 - browse：7483

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： FDA warns J&J's Abiomed: We will regulate your software

entertainment

WSS

Senate committee scrutinizes Medicare Advantage brokers

Impact of Dobbs ruling felt at reproductive medicine meeting

How climate

STAT Readout Newsletter: Today's biggest biotech updates

CEOs share strategies for surviving biotech slump

Antivenom research: Lessons from HIV applied in search for universal antidote

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare reduced heart disease by changing how it pays doctors

Peter Hotez and the public health issue of online harassment

New documents shed light on MD Anderson Cancer Institute feud

How one medical school became remarkably diverse

A solution to the after

The high cost of giving birth even with insurance

How climate

Hollywood unions extend contract negotiations for actors

UnitedHealth’s board chair also owns a personal investment firm

focus

FDA gives detailed accounting of AI

A new nitrogen execution bill also undermines medical licensing

Why health workers in Gaza are injured or die at high rates